Flupentixol
- 1 lab in 1 country
- Funder: Novo Nordisk Fonden
- Humans1
Associations
1Major adverse cardiovascular events
downin humans1
1 study
Major adverse cardiovascular events
downin humans1
Flupentixol lowers the risk of major adverse cardiovascular events in humans (IRR 0.54, 95% CI 0.45 to 0.66).
“lower for treatment with flupentixol (0.54, 95% CI 0.45 to 0.66)”
Humanscompared with risperidone, first 30 days of treatment30 days
Journal of the American Heart Association1 Sep 2015
Latest
Journal of the American Heart Association
Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons
Cohort study of 91,774 peoplePopulations